Catalog No.
DHB34103
Expression system
Mammalian Cells
Species reactivity
Human
Isotype
Fusion - [TNFRSF13B (tumor necrosis factor receptor (TNFR) superfamily member 13B, TACI, transmembrane activator and CAML Interactor)]2 - IGHG1 Fc (Fragment constant)
Target
TNF- and APOL-related leukocyte expressed ligand 2, APRIL, CD256, Tumor necrosis factor ligand superfamily member 13, TNF-related death ligand 1, TALL-2, TNFSF13, ZTNF2, A proliferation-inducing ligand, TALL2, TRDL-1, BAFF, ZTNF4, BLYS, Tumor necrosis factor ligand superfamily member 13B, Dendritic cell-derived TNF-like molecule, TALL-1, TNF- and APOL-related leukocyte expressed ligand 1, BLyS, B lymphocyte stimulator, TNFSF13B, CD257, TNFSF20, TALL1, B-cell-activating factor
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
O75888 & Q9Y275
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
TACI-Fc, TACI-Ig, CAS: 845264-92-8
Clone ID
Atacicept
[The highlights of nephrology in 2024]., PMID:40208671
Telitacicept as an alternative to non-steroidal immunosuppressive therapies in the treatment of myasthenia gravis: a study on clinical efficacy and steroid-sparing effect., PMID:40196119
Updates on Glomerular Diseases: A Summary of Inaugural GlomCon Hawaii 2024., PMID:40182025
Comparative efficacy and safety of different recommended doses of telitacicept in patients with systemic lupus erythematosus in China: a systematic review and meta-analysis., PMID:39867893
A first-in-human, randomized study of the safety, pharmacokinetics and pharmacodynamics of povetacicept, an enhanced dual BAFF/APRIL antagonist, in healthy adults., PMID:39494621
Long-Term Results from an Open-Label Extension Study of Atacicept for the Treatment of IgA Nephropathy., PMID:39462308
Current status of BAFF targeting immunotherapy in B-cell neoplasm., PMID:39222149
Telitacicept: A novel horizon in targeting autoimmunity and rheumatic diseases., PMID:39146891
Anti-B-Cell-Activating Factor (BAFF) Therapy: A Novel Addition to Autoimmune Disease Management and Potential for Immunomodulatory Therapy in Warm Autoimmune Hemolytic Anemia., PMID:39062171
A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy., PMID:38552841
Advances in the treatment of IgA nephropathy with biological agents., PMID:38450299
The role of BAFF and APRIL in IgA nephropathy: pathogenic mechanisms and targeted therapies., PMID:38362118
The contribution of a proliferation-inducing ligand (APRIL) and other TNF superfamily members in pathogenesis and progression of IgA nephropathy., PMID:38053976
Identifying lupus Patient Subsets Through Immune Cell Deconvolution of Gene Expression Data in Two Atacicept Phase II Studies., PMID:37710418
Advances in natural products and antibody drugs for SLE: new therapeutic ideas., PMID:37492083
Population pharmacokinetics of atacicept in systemic lupus erythematosus: An analysis of three clinical trials., PMID:37332136
Features of Isoforms of Human Soluble TACI., PMID:37272840
Emerging role of monoclonal antibodies in the treatment of IgA nephropathy., PMID:37183663
Dual Role of B Cells in Multiple Sclerosis., PMID:36768658
Evaluation of Variation in the Performance of GFR Slope as a Surrogate End Point for Kidney Failure in Clinical Trials that Differ by Severity of CKD., PMID:36754007
Ocrelizumab Treatment Modulates B-Cell Regulating Factors in Multiple Sclerosis., PMID:36702538
Kinetics of free and ligand-bound atacicept in human serum., PMID:36532058
B cell depletion and inhibition in systemic lupus erythematosus., PMID:36342225
Atacicept-it's not over until the wolf-lady sings (or maybe howls)., PMID:36087007
Randomized Phase II JANUS Study of Atacicept in Patients With IgA Nephropathy and Persistent Proteinuria., PMID:35967104
Efficacy and Safety of Biologic Agents for Lupus Nephritis: A Systematic Review and Meta-analysis., PMID:35699520
[Advances of using antibody against B cell activating factor for treatment of autoimmune diseases]., PMID:35355463
Telitacicept as a BLyS/APRIL dual inhibitor for autoimmune disease., PMID:34519594
Case Report: In Situ Expression of a Proliferation-Inducing Ligand in Neuromyelitis Optica., PMID:34421813
Identifying Safety Thresholds for Immunosuppressive Drugs: Applying Insights from Primary Antibody Deficiencies to Mitigate Adverse Events in Secondary Antibody Deficiencies Using Mathematical Modeling of Preclinical and Early Clinical Data., PMID:34328632
An Update on the Management of Childhood-Onset Systemic Lupus Erythematosus., PMID:34244988
CNS Autoimmune Responses in BCMA-Deficient Mice Provide Insight for the Failure of Atacicept in MS., PMID:33649164
Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosus., PMID:33547784
Emerging B-Cell Therapies in Systemic Lupus Erythematosus., PMID:33488082
Commentary: Systematic Review of Safety and Efficacy of Atacicept in Treating Immune-Mediated Disorders., PMID:33262771
BAFF 60-mer, and Differential BAFF 60-mer Dissociating Activities in Human Serum, Cord Blood and Cerebrospinal Fluid., PMID:33240880
Kidney outcomes for children with lupus nephritis., PMID:32725543
Hspa13 Promotes Plasma Cell Production and Antibody Secretion., PMID:32547538
Systematic Review of Safety and Efficacy of Atacicept in Treating Immune-Mediated Disorders., PMID:32265917
Current Understanding and Unknown Aspects of the Treatment of Granulomatosis with Polyangiitis (Wegener's Granulomatosis): Opportunities for Future Studies., PMID:32228425
Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study., PMID:32107560
The safety and efficacy of biologic agents in treatment of systemic lupus erythematosus: A network meta-analysis., PMID:31777515
Failed B cell survival factor trials support the importance of memory B cells in multiple sclerosis., PMID:31617269
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Atacicept in a Randomized Trial in Healthy Caucasian and Japanese Subjects., PMID:31529406
Integrated safety profile of atacicept: an analysis of pooled data from the atacicept clinical trial programme., PMID:31528843
No interactions between heparin and atacicept, an antagonist of B cell survival cytokines., PMID:31355456
Site-specific N- and O-glycosylation analysis of atacicept., PMID:31349756
Therapies for multiple sclerosis targeting B cells., PMID:31044580
BAFF promotes T cell activation through the BAFF-BAFF-R-PI3K-Akt signaling pathway., PMID:30921706
Desensitization and treatment with APRIL/BLyS blockade in rodent kidney transplant model., PMID:30735519
For research use only. Not for human or drug use.
